| Similar Articles |
|---|
 |
The Motley Fool
December 27, 2006
Brian Lawler |
Alkermes' Japanese Opportunity With Japan commanding over 10% of global pharmaceutical sales and Risperdal sales gaining ground, there will be big bucks for Alkermes if Risperdal can gain marketing approval over there.   |
The Motley Fool
September 23, 2009
Robert Steyer |
Alkermes Needs Some Financial Alchemy After a string of research and marketing disappointments, the company's CEO departs. |
The Motley Fool
July 6, 2007
Brian Lawler |
Another Round for Alkermes' Alcohol Fight Alkermes advances the development of another drug. Investors, take note. |
The Motley Fool
October 13, 2010
Brian Orelli |
Don't Get Addicted to Alkermes' Low Revenue Vivitrol's launch and the approval of Bydureon will drive revenue -- and Alkmeres' stock price -- in the future. |
The Motley Fool
March 20, 2008
Brian Lawler |
The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting. |
The Motley Fool
August 27, 2009
Brian Orelli |
Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan |
The Motley Fool
February 7, 2005
Brian Gorman |
Alkermes Is Coming of Age The drug delivery company may soon have its own drug on the market. |
The Motley Fool
June 11, 2007
Brian Lawler |
More Air for Alkermes The biopharmaceutical drug delivery expert brings another drug into clinic stage testing. Investors, take note. |
The Motley Fool
June 27, 2005
Brian Gorman |
Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience. |
The Motley Fool
February 11, 2009
Brian Orelli |
The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder. |
The Motley Fool
August 27, 2008
Brian Orelli |
Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note. |
The Motley Fool
May 9, 2011
Brian Orelli |
In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million. |
The Motley Fool
May 19, 2009
Brian Orelli |
Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies. |
The Motley Fool
April 8, 2005
Stephen D. Simpson |
Alkermes' Alcohol Alchemy A new formulation of an old drug could help alcoholics and make shareholders happy. |
The Motley Fool
October 30, 2007
Brian Lawler |
Lasting Longer Courtesy of Elan Elan announces that partner Johnson & Johnson has filed a marketing application for a once-a-month form of its anti-psychotic drug Invega. Investors, take note. |
The Motley Fool
August 3, 2007
Brian Lawler |
Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
April 15, 2011
Luke Timmerman |
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe? |
The Motley Fool
August 24, 2007
Brian Orelli |
Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note. |
The Motley Fool
January 8, 2009
Brian Orelli |
FDA Toys With Lilly, and Investors, Again Eli Lilly will have to wait a little longer. |
The Motley Fool
February 10, 2009
Brian Orelli |
Roses and Candy From the FDA? Some drugmakers expect the FDA to bestow its kiss of approval this month. Read on to see who. |
The Motley Fool
December 14, 2009
Brian Orelli |
Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa. |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
The Motley Fool
April 15, 2011
Brian Orelli |
Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
October 28, 2011
Brian Orelli |
Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever. |
The Motley Fool
July 8, 2011
Luke Timmerman |
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies? |
The Motley Fool
October 22, 2007
Brian Lawler |
Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future. |
The Motley Fool
January 2, 2012
Anders Bylund |
What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012. |
The Motley Fool
March 2, 2005
Bill Mann |
How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns. |
The Motley Fool
June 27, 2006
Brian Lawler |
Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity. |
The Motley Fool
February 16, 2007
Brian Lawler |
Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note. |
The Motley Fool
January 26, 2006
Stephen D. Simpson |
Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option. |
The Motley Fool
October 17, 2007
Brian Orelli |
FDA Warning Might Be a Buying Opportunity The 3%-4% drops in the stock prices of Amylin and Alkermes, Amylin's partner in the development of a sustained-release version of Byetta, could be a good buying opportunity for investors. |
